Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Cancer Invest ; 42(2): 141-154, 2024 Feb.
Article En | MEDLINE | ID: mdl-38486421

We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor. A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.


B7-H1 Antigen , Gastrointestinal Neoplasms , Hepatitis A Virus Cellular Receptor 2 , Immune Checkpoint Proteins , Neuroendocrine Tumors , Pancreatic Neoplasms , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , B7-H1 Antigen/analysis , B7-H1 Antigen/metabolism , DNA Repair , Gastrointestinal Neoplasms/chemistry , Gastrointestinal Neoplasms/pathology , Hepatitis A Virus Cellular Receptor 2/analysis , Hepatitis A Virus Cellular Receptor 2/metabolism , Immune Checkpoint Proteins/analysis , Immune Checkpoint Proteins/metabolism , Lymphocyte Activation Gene 3 Protein/analysis , Lymphocyte Activation Gene 3 Protein/metabolism , Neuroendocrine Tumors/chemistry , Neuroendocrine Tumors/pathology , OX40 Ligand/analysis , OX40 Ligand/metabolism , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/pathology , Retrospective Studies , Immunohistochemistry , Neoplasm Grading
2.
JCI Insight ; 6(13)2021 07 08.
Article En | MEDLINE | ID: mdl-34236044

Diagnosis of organ transplant rejection relies upon biopsy approaches to confirm alloreactive T cell infiltration in the graft. Immune molecular monitoring is under investigation to screen for rejection, though these techniques have suffered from low specificity and lack of spatial information. ImmunoPET utilizing antibodies conjugated to radioisotopes has the potential to improve early and accurate detection of graft rejection. ImmunoPET is capable of noninvasively visualizing the dynamic distribution of cells expressing specific immune markers in the entire body over time. In this work, we identify and characterize OX40 as a surrogate biomarker for alloreactive T cells in organ transplant rejection and monitor its expression by utilizing immunoPET. In a dual murine heart transplant model that has both syngeneic and allogeneic hearts engrafted in bilateral ear pinna on the recipients, OX40 immunoPET clearly depicted alloreactive T cells in the allograft and draining lymph node that were not observed in their respective isograft counterparts. OX40 immunoPET signals also reflected the subject's immunosuppression level with tacrolimus in this study. OX40 immunoPET is a promising approach that may bridge molecular monitoring and morphological assessment for improved transplant rejection diagnosis.


Graft Rejection , Heart Transplantation/adverse effects , Monitoring, Immunologic/methods , OX40 Ligand , Positron-Emission Tomography/methods , T-Lymphocytes/immunology , Animals , Antigens, Differentiation/analysis , Biomarkers/analysis , Early Diagnosis , Gene Expression Profiling/methods , Graft Rejection/diagnosis , Graft Rejection/immunology , Humans , Mass Screening/methods , Mice , OX40 Ligand/analysis , OX40 Ligand/immunology , Radioimmunoassay/methods
3.
BMC Cardiovasc Disord ; 19(1): 272, 2019 11 29.
Article En | MEDLINE | ID: mdl-31783796

BACKGROUND: Coronary heart disease is related to sudden death caused by multi-factors and a major threat to human health.This study explores the role of OX40L and ICAM-1 in the stability of coronary plaques and their relationship with sudden coronary death. METHODS: A total of 118 human coronary arteries with different degrees of atherosclerosis and/or sudden coronary death comprised the experimental group and 28 healthy subjects constituted the control group were isolated from patients. The experimental group was subdivided based on whether the cause of death was sudden coronary death and whether it was accompanied by thrombosis, plaque rupture, plaque outflow and other secondary changes: group I: patients with coronary atherosclerosis but not sudden coronary death, group II: sudden coronary death without any of the secondary changes mentioned above, group III: sudden coronary death with coronary artery atherosclerotic lesions accompanied by either of the above secondary changes. The histological structure of the coronary artery was observed under a light microscope after routine HE staining, and the related indexes of atherosclerotic plaque lesions were assessed by image analysis software. The expressions of OX40L and ICAM-1 were detected by real-time quantitative PCR (RT-PCR), immunohistochemistry (IHC) and Western blotting, and the correlations between the expressions and the stability of coronary atherosclerotic plaque and sudden coronary death were analyzed. RESULTS: (1) The expression of OX40L protein in the control group and the three experimental groups showed an increasing trend, and the difference between groups was statistically significant (P < 0.05). (2) The expression of the ICAM-1 protein in the control group and the three experimental groups showed a statistically significant (P < 0.05) increasing trend. (3) The expression of OX40L and ICAM-1 mRNAs increased in the control and the three experimental groups and the difference was statistically significant (P < 0.05). CONCLUSION: The expression of OX40L and ICAM-1 proteins and mRNAs is positively correlated with the stability of coronary atherosclerotic plaque and sudden coronary death.


Coronary Artery Disease/metabolism , Coronary Vessels/chemistry , Death, Sudden, Cardiac/etiology , Intercellular Adhesion Molecule-1/analysis , OX40 Ligand/analysis , Plaque, Atherosclerotic , Adult , Aged , Aged, 80 and over , Biomarkers/analysis , Case-Control Studies , Coronary Artery Disease/complications , Coronary Artery Disease/mortality , Coronary Artery Disease/pathology , Coronary Vessels/pathology , Death, Sudden, Cardiac/pathology , Female , Humans , Intercellular Adhesion Molecule-1/genetics , Male , Middle Aged , OX40 Ligand/genetics , Prognosis , Risk Assessment , Risk Factors , Rupture, Spontaneous , Up-Regulation
4.
AAPS J ; 16(4): 625-33, 2014 Jul.
Article En | MEDLINE | ID: mdl-24752719

Data generated using various immunoassay methods are an integral part of the development of protein therapeutics. These assays are used in clinical and preclinical studies to establish the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics as well as to assess the immunogenicity properties of a therapeutic. PK assays measure therapeutic levels post-administration which is essential for understanding the effective dose and dose regimen for a therapeutic. Anti-OX40L is a fully humanized monoclonal antibody designed for the potential treatment of an autoimmune disease. The anti-OX40L human PK assay is required to be sensitive, robust, and precise. To address challenges due to assay sensitivity and reproducibility, as well as assay technology limitations, during development of the anti-OX40L human PK assay, three different assays, including an MSD-based electrochemiluminescence assay (ECLA), a fluorometric enzyme-linked immunosorbent assay (ELISA), and a colorimetric ELISA, were evaluated. The MSD-based assay was the most sensitive but posed risk of inter-well signal crosstalk. The fluorescence ELISA fell short on reproducibility. The colorimetric ELISA was ultimately chosen for supporting sample analysis. This paper presents characterization data obtained from each of these assay formats, challenges that were encountered in the development of the assay, and the rationale for selecting the ultimate assay format.


Chemistry, Pharmaceutical/methods , Pharmacokinetics , Antibodies/analysis , Antibodies, Monoclonal/analysis , Antibodies, Monoclonal/pharmacokinetics , Colorimetry , Enzyme-Linked Immunosorbent Assay , Fluorescence , Humans , Luminescence , OX40 Ligand/analysis , OX40 Ligand/pharmacokinetics , Reproducibility of Results
...